{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:30:53Z","timestamp":1777552253055,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,6]]},"DOI":"10.7759\/cureus.50065","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T21:28:59Z","timestamp":1701898139000},"source":"Crossref","is-referenced-by-count":2,"title":["Role of Liraglutide Use in Patients With Heart Failure"],"prefix":"10.7759","author":[{"given":"Sanjana","family":"Allam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Sartaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba","family":"Moquim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ammar","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Bustos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Lakkimsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avneet K","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-017-0351-y","article-title":"Acute heart failure: definition, classification and epidemiology","volume":"14","author":"Kurmani S","year":"2017","unstructured":"Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017, 14:385-92. 10.1007\/s11897-017-0351-y","journal-title":"Curr Heart Fail Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.04.154","article-title":"Epidemiology and pathogenesis of heart failure with preserved ejection fraction","volume":"21","author":"Nair N","year":"2020","unstructured":"Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Reviews in cardiovascular medicine. 2020, 21:531-40. 10.31083\/j.rcm.2020.04.154","journal-title":"Reviews in cardiovascular medicine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2020.03.023","article-title":"Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction","volume":"49","author":"G\u00f6k G","year":"2020","unstructured":"G\u00f6k G, K\u0131l\u0131\u00e7 S, Sinan \u00dcY, Turkoglu E, Kemal H, Zoghi M. Epidemiology and clinical characteristics of hospitalized elderly patients for heart failure with reduced, mid-range and preserved ejection fraction. Heart Lung. 2020, 49:495-500. 10.1016\/j.hrtlng.2020.03.023","journal-title":"Heart Lung"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S170873","article-title":"Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden","volume":"11","author":"Lindmark K","year":"2019","unstructured":"Lindmark K, Boman K, Olofsson M, et al.. Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden. Clin Epidemiol. 2019, 11:231-44. 10.2147\/CLEP.S170873","journal-title":"Clin Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger VL","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021, 128:1421-34. 10.1161\/CIRCRESAHA.121.318172","journal-title":"Circ Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.000346","article-title":"GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study","volume":"7","author":"Margulies KB","year":"2014","unstructured":"Margulies KB, Anstrom KJ, Hernandez AF, Redfield MM, Shah MR, Braunwald E, Cappola TP. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail. 2014, 7:673-9. 10.1161\/CIRCHEARTFAILURE.114.000346","journal-title":"Circ Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability","volume":"34 Suppl 2","author":"Garber AJ","year":"2011","unstructured":"Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011, 34 Suppl 2:S279-84. 10.2337\/dc11-s231","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure","author":"Ferreira JP","year":"2023","unstructured":"Ferreira JP, Sharma A, Butler J, et al.. Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. J Clin Endocrinol Metab. 2023, dgad398. 10.1210\/clinem\/dgad398","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo JM","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021, 12:2042018821997320. 10.1177\/2042018821997320","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4020492","article-title":"GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes","volume":"2018","author":"Del Olmo-Garcia MI","year":"2018","unstructured":"Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018, 2018:4020492. 10.1155\/2018\/4020492","journal-title":"J Diabetes Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy L","year":"2015","unstructured":"Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015, 4:212283. 10.7573\/dic.212283","journal-title":"Drugs Context"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014, 11:202-30. 10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can J","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014, 38:784-93. 10.1038\/ijo.2013.162","journal-title":"Int J Obes (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren JR","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SB, et al.. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021, 384:1719-30. 10.1056\/NEJMoa2028198","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. The","volume":"374","author":"Astrup A","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, et al.. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. The. Lancet. 2009, 374:1606-16. 10.1016\/S0140-6736(09)61375-1","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial","volume":"327","author":"Rubino DM","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al.. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial. JAMA. 2022, 327:138-50. 10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane WV","year":"2019","unstructured":"Tamborlane WV, Barrientos-P\u00e9rez M, Fainberg U, et al.. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019, 381:637-46. 10.1056\/NEJMoa1903822","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman AM","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris GL, et al.. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022, 145:575-85. 10.1161\/CIRCULATIONAHA.121.055459","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright AK","year":"2022","unstructured":"Wright AK, Carr MJ, Kontopantelis E, et al.. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022, 45:909-18. 10.2337\/dc21-1113","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2019.07.005","article-title":"Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes","volume":"62","author":"Garg V","year":"2019","unstructured":"Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019, 62:349-57. 10.1016\/j.pcad.2019.07.005","journal-title":"Prog Cardiovasc Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01385-5","article-title":"Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence","volume":"20","author":"Natali A","year":"2021","unstructured":"Natali A, Nesti L, Tric\u00f2 D, Ferrannini E. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol. 2021, 20:196. 10.1186\/s12933-021-01385-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular\u00a0outcomes in patients with diabetes with or without heart\u00a0failure","volume":"75","author":"Marso SP","year":"2020","unstructured":"Marso SP, Baeres FM, Bain SC, et al.. Effects of liraglutide on cardiovascular\u00a0outcomes in patients with diabetes with or without heart\u00a0failure. J Am Coll Cardiol. 2020, 75:1128-41. 10.1016\/j.jacc.2019.12.063","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves JS","year":"2023","unstructured":"Neves JS, Vasques-N\u00f3voa F, Borges-Canha M, et al.. Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial. Diabetes Obes Metab. 2023, 25:189-97. 10.1111\/dom.14862","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies KB","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, et al.. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016, 316:500-8. 10.1001\/jama.2016.10260","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/14017431.2020.1751873","article-title":"Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events","volume":"54","author":"Tougaard RS","year":"2020","unstructured":"Tougaard RS, Jorsal A, Tarnow L, et al.. Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scand Cardiovasc J. 2020, 54:294-9. 10.1080\/14017431.2020.1751873","journal-title":"Scand Cardiovasc J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal A","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, et al.. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017, 19:69-77. 10.1002\/ejhf.657","journal-title":"Eur J Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041159","article-title":"New insights into the use of liraglutide-impact on cardiovascular risk and microvascular outcomes","volume":"11","author":"Wronka M","year":"2023","unstructured":"Wronka M, Krzemi\u0144ska J, M\u0142ynarska E, Rysz J, Franczyk B. New insights into the use of liraglutide-impact on cardiovascular risk and microvascular outcomes. Biomedicines. 2023, 11:1159. 10.3390\/biomedicines11041159","journal-title":"Biomedicines"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson LE","year":"2013","unstructured":"Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013, 3:e001986. 10.1136\/bmjopen-2012-001986","journal-title":"BMJ Open"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MM, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials. The Lancet Diabetes & endocrinology. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"The Lancet Diabetes & endocrinology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay SM","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al.. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019, 140:e294-324. 10.1161\/CIR.0000000000000691","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107 PM","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, et al.. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018, 20:853-72. 10.1002\/ejhf.1170","journal-title":"Eur J Heart Fail"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 collaborators","year":"2015","unstructured":"Global Burden of Disease Study 2013 collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015, 386:743-800. 10.1016\/S0140-6736(15)60692-4","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier JJ","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012, 8:728-42. 10.1038\/nrendo.2012.140","journal-title":"Nat Rev Endocrinol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al.. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021, 20:189. 10.1186\/s12933-021-01366-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019, 139:2022-31. 10.1161\/CIRCULATIONAHA.118.038868","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01784-w","article-title":"Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction","volume":"22","author":"Gonzalez J","year":"2023","unstructured":"Gonzalez J, Bates BA, Setoguchi S, Gerhard T, Dave CV. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovasc Diabetol. 2023, 22:54. 10.1186\/s12933-023-01784-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.","volume":"6","author":"Bethel MA","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, et al.. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. . The Lancet Diabetes and Endocrinology. 2018, 6:105-13. 10.1016\/S2213-8587(17)30412-6","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail. 2023, 11:1000-10. 10.1016\/j.jchf.2023.05.010","journal-title":"JACC Heart Fail"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.02.005","article-title":"Baseline characteristics of patients enrolled in the exenatide study of cardiovascular event lowering (EXSCEL)","volume":"187","author":"Mentz RJ","year":"2017","unstructured":"Mentz RJ, Bethel MA, Gustavson S, et al.. Baseline characteristics of patients enrolled in the exenatide study of cardiovascular event lowering (EXSCEL). Am Heart J. 2017, 187:1-9. 10.1016\/j.ahj.2017.02.005","journal-title":"Am Heart J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009579","article-title":"Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes","volume":"5","author":"Smits MM","year":"2015","unstructured":"Smits MM, Tonneijck L, Muskiet MH, et al.. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open. 2015, 5:e009579. 10.1136\/bmjopen-2015-009579","journal-title":"BMJ Open"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire DK","year":"2023","unstructured":"McGuire DK, Busui RP, Deanfield J, et al.. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023, 25:1932-41. 10.1111\/dom.15058","journal-title":"Diabetes Obes Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004885","article-title":"A protocol for a randomised, double-blind, placebo-controlled study of the effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes (the LIVE study)","volume":"4","author":"Jorsal A","year":"2014","unstructured":"Jorsal A, Wiggers H, Holmager P, et al.. A protocol for a randomised, double-blind, placebo-controlled study of the effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes (the LIVE study). BMJ Open. 2014, 4:e004885. 10.1136\/bmjopen-2014-004885","journal-title":"BMJ Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211147-role-of-liraglutide-use-in-patients-with-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:34Z","timestamp":1707509314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211147-role-of-liraglutide-use-in-patients-with-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.50065","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}